CO2021013699A2 - Líneas celulares productoras diseñadas genéticamente y métodos de elaboración y uso de las mismas - Google Patents
Líneas celulares productoras diseñadas genéticamente y métodos de elaboración y uso de las mismasInfo
- Publication number
- CO2021013699A2 CO2021013699A2 CONC2021/0013699A CO2021013699A CO2021013699A2 CO 2021013699 A2 CO2021013699 A2 CO 2021013699A2 CO 2021013699 A CO2021013699 A CO 2021013699A CO 2021013699 A2 CO2021013699 A2 CO 2021013699A2
- Authority
- CO
- Colombia
- Prior art keywords
- cell lines
- genetically engineered
- methods
- making
- producer cell
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 241000702421 Dependoparvovirus Species 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962833548P | 2019-04-12 | 2019-04-12 | |
| US201962839207P | 2019-04-26 | 2019-04-26 | |
| US202062979483P | 2020-02-21 | 2020-02-21 | |
| PCT/US2020/027489 WO2020210507A1 (en) | 2019-04-12 | 2020-04-09 | Engineered producer cell lines and methods of making and using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021013699A2 true CO2021013699A2 (es) | 2021-10-29 |
Family
ID=70465550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0013699A CO2021013699A2 (es) | 2019-04-12 | 2021-10-14 | Líneas celulares productoras diseñadas genéticamente y métodos de elaboración y uso de las mismas |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US12018288B2 (https=) |
| EP (2) | EP4603579A3 (https=) |
| JP (2) | JP7560475B2 (https=) |
| KR (1) | KR20210152514A (https=) |
| CN (1) | CN113966395B (https=) |
| AU (1) | AU2020270960B2 (https=) |
| BR (1) | BR112021020391A2 (https=) |
| CA (1) | CA3136246A1 (https=) |
| CO (1) | CO2021013699A2 (https=) |
| IL (1) | IL287106A (https=) |
| MX (1) | MX2021012489A (https=) |
| PH (1) | PH12021552577A1 (https=) |
| SG (1) | SG11202110904PA (https=) |
| TW (1) | TWI859216B (https=) |
| WO (1) | WO2020210507A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4189077A1 (en) | 2020-07-30 | 2023-06-07 | Shape Therapeutics Inc. | Stable cell lines for inducible production of raav virions |
| WO2023019168A1 (en) | 2021-08-11 | 2023-02-16 | Ultragenyx Pharmaceutical Inc. | Compositions and methods for treating a muscular dystrophy |
| AU2022373653A1 (en) | 2021-10-18 | 2024-05-02 | Regeneron Pharmaceuticals, Inc. | Eukaryotic cells comprising adenovirus-associated virus polynucleotides |
| US20250019668A1 (en) | 2021-10-29 | 2025-01-16 | Ultragenyx Pharmaceutical Inc. | Engineered cell lines for increased production of recombinant adeno-associated virus (raav) |
| CN119137263A (zh) | 2022-03-07 | 2024-12-13 | 奥特吉尼克斯制药公司 | 改进的分批aav产生系统和方法 |
| WO2025078616A1 (en) * | 2023-10-12 | 2025-04-17 | Cevec Pharmaceuticals Gmbh | Cellular factors affecting recombinant aav production |
| WO2025226558A1 (en) | 2024-04-22 | 2025-10-30 | Ultragenyx Pharmaceutical Inc. | Multi-step filtration and clarification methods for recombinant adeno-associated virus purification |
| WO2026078664A1 (en) | 2024-10-10 | 2026-04-16 | Instituto De Biologia Experimental E Tecnológica (Ibet) | Transcription factor enhancing recombinant adeno-associated virus production, products, methods and uses thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US5387484A (en) | 1992-07-07 | 1995-02-07 | International Business Machines Corporation | Two-sided mask for patterning of materials with electromagnetic radiation |
| US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| AU707866B2 (en) | 1994-12-06 | 1999-07-22 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant AAV vectors |
| US5741683A (en) | 1995-06-07 | 1998-04-21 | The Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
| US5688676A (en) | 1995-06-07 | 1997-11-18 | Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
| AU741605B2 (en) | 1996-12-18 | 2001-12-06 | Targeted Genetics Corporation | AAV split-packaging genes and cell lines comprising such genes for use in the production of recombinant AAV vectors |
| US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
| JP2001514845A (ja) * | 1997-09-05 | 2001-09-18 | ターゲティッド ジェネティクス コーポレイション | 組換えａａｖベクターの高力価ヘルパーなし調製物を生成するための方法 |
| AU764130B2 (en) | 1998-10-27 | 2003-08-14 | Crucell Holland B.V. | Improved AAV vector production |
| DE19905501B4 (de) | 1999-02-10 | 2005-05-19 | MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie | Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels |
| WO2004075861A2 (en) | 2003-02-26 | 2004-09-10 | Children's Hospital, Inc. | Recombinant adeno-associated virus production |
| WO2006125830A2 (en) * | 2005-05-27 | 2006-11-30 | Evotec Neurosciences Gmbh | Kcnn3 as diagnostic and therapeutic target for neurodegenerative diseases |
| EP2311967B1 (en) | 2005-10-20 | 2017-09-20 | UniQure IP B.V. | Improved AAV vectors produced in insect cells |
| US8188060B2 (en) | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
| KR20150133695A (ko) | 2013-02-05 | 2015-11-30 | 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 | 바이러스 제조를 위한 세포주 및 이의 사용 방법 |
| CN104592364B (zh) * | 2013-10-30 | 2018-05-01 | 北京大学 | 定点突变和定点修饰的腺相关病毒、其制备方法及应用 |
| GB201401707D0 (en) * | 2014-01-31 | 2014-03-19 | Sec Dep For Health The | Adeno-associated viral vectors |
| US20160319277A1 (en) | 2015-01-28 | 2016-11-03 | The Johns Hopkins University | METHODS OF IMPROVED PROTEIN PRODUCTION USING MIRNAs AND SIRNAs |
| PL3436593T3 (pl) | 2016-03-28 | 2023-03-27 | Ultragenyx Pharmaceutical Inc. | Sposoby inaktywacji termicznej adenowirusów |
| US20190290710A1 (en) | 2016-07-12 | 2019-09-26 | Dimension Therapeutics, Inc. | Use of glucocorticoid analogs to enhance recombinant adeno-associated virus yield |
| ES3012649T3 (en) | 2016-10-14 | 2025-04-09 | Ultragenyx Pharmaceutical Inc | Use of tonicifying agents to enhance recombinant adeno-associated virus yield |
| JP7142643B2 (ja) | 2017-03-22 | 2022-09-27 | ウルトラジェニックス ファーマシューティカル インコーポレイテッド | Ｈｄａｃ阻害剤またはｒｅｐタンパク質を伴う細胞培養方法 |
| US20200048641A1 (en) | 2017-03-22 | 2020-02-13 | Ultragenyx Pharmaceutical Inc. | Methods for enhancing yield of recombinant adeno-associated virus |
| JP7218303B2 (ja) | 2017-05-09 | 2023-02-06 | ウルトラジェニックス ファーマシューティカル インコーポレイテッド | トランスフェクション試薬を生成するための拡大可能な方法 |
| US20200340013A1 (en) | 2018-01-19 | 2020-10-29 | The University Of North Carolina At Chapel Hill | Methods and compositions for inhibition of innate immune response associated with aav transduction |
| WO2020219543A1 (en) | 2019-04-26 | 2020-10-29 | The Regents Of The University Of California | Cells for enhanced production of adeno-associated virus |
| US20250019668A1 (en) * | 2021-10-29 | 2025-01-16 | Ultragenyx Pharmaceutical Inc. | Engineered cell lines for increased production of recombinant adeno-associated virus (raav) |
-
2020
- 2020-04-09 AU AU2020270960A patent/AU2020270960B2/en active Active
- 2020-04-09 WO PCT/US2020/027489 patent/WO2020210507A1/en not_active Ceased
- 2020-04-09 KR KR1020217036581A patent/KR20210152514A/ko active Pending
- 2020-04-09 MX MX2021012489A patent/MX2021012489A/es unknown
- 2020-04-09 US US16/844,475 patent/US12018288B2/en active Active
- 2020-04-09 CN CN202080028310.8A patent/CN113966395B/zh active Active
- 2020-04-09 EP EP25183274.7A patent/EP4603579A3/en active Pending
- 2020-04-09 CA CA3136246A patent/CA3136246A1/en active Pending
- 2020-04-09 BR BR112021020391A patent/BR112021020391A2/pt unknown
- 2020-04-09 JP JP2021559793A patent/JP7560475B2/ja active Active
- 2020-04-09 EP EP20722185.4A patent/EP3953458A1/en active Pending
- 2020-04-09 PH PH1/2021/552577A patent/PH12021552577A1/en unknown
- 2020-04-09 SG SG11202110904PA patent/SG11202110904PA/en unknown
- 2020-04-10 TW TW109112259A patent/TWI859216B/zh active
-
2021
- 2021-10-07 IL IL287106A patent/IL287106A/en unknown
- 2021-10-14 CO CONC2021/0013699A patent/CO2021013699A2/es unknown
-
2024
- 2024-05-09 US US18/659,358 patent/US20240376440A1/en active Pending
- 2024-06-11 JP JP2024094278A patent/JP7706607B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021012489A (es) | 2021-11-12 |
| US20200325455A1 (en) | 2020-10-15 |
| AU2020270960B2 (en) | 2026-01-29 |
| IL287106A (en) | 2021-12-01 |
| JP2022526646A (ja) | 2022-05-25 |
| US20240376440A1 (en) | 2024-11-14 |
| JP7560475B2 (ja) | 2024-10-02 |
| AU2020270960A1 (en) | 2021-11-04 |
| US12018288B2 (en) | 2024-06-25 |
| KR20210152514A (ko) | 2021-12-15 |
| EP3953458A1 (en) | 2022-02-16 |
| BR112021020391A2 (pt) | 2022-02-08 |
| SG11202110904PA (en) | 2021-10-28 |
| TWI859216B (zh) | 2024-10-21 |
| JP2024107295A (ja) | 2024-08-08 |
| EP4603579A3 (en) | 2025-12-10 |
| TW202104593A (zh) | 2021-02-01 |
| WO2020210507A1 (en) | 2020-10-15 |
| PH12021552577A1 (en) | 2022-04-04 |
| CN113966395A (zh) | 2022-01-21 |
| CA3136246A1 (en) | 2020-10-15 |
| JP7706607B2 (ja) | 2025-07-11 |
| EP4603579A2 (en) | 2025-08-20 |
| CN113966395B (zh) | 2025-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021013699A2 (es) | Líneas celulares productoras diseñadas genéticamente y métodos de elaboración y uso de las mismas | |
| BR112021021725A2 (pt) | Proteínas policlonais recombinantes e métodos de uso das mesmas | |
| CO2021006362A2 (es) | Construcciones de ácido nucleico y métodos de uso | |
| MX2019006438A (es) | Produccion de celulas modificadas para terapia de celulas adoptivas. | |
| CL2018000740A1 (es) | Vectores del factor viii del virus adeno-asociado, partículas víricas asociadas y formulaciones terapéuticas que los comprenden | |
| AR118560A2 (es) | Métodos y composiciones que comprenden polipéptidos recombinantes purificados | |
| BR112021016984A2 (pt) | Receptores de antígeno quimérico direcionados a dll3 e agentes de ligação | |
| MX2023006395A (es) | Celulas dise?adas geneticamente y usos de estas. | |
| BR112022005963A2 (pt) | Células com expressão de transgenes sustentada | |
| MX2022001977A (es) | Poblaciones de celulas t gamma delta t ex vivo. | |
| MX2018003144A (es) | Dominios de superfamilia de inmunoglobulina de variante ajustable y terapia con células genéticamente modificadas. | |
| ECSP22056585A (es) | Variantes de alfa-glucosidasa ácida diseñadas por ingeniería | |
| BR112022009290A2 (pt) | Terapia para malignidades de células hematopoiéticas com o uso de células t geneticamente modificadas visando cd70 | |
| PE20211660A1 (es) | Neoantigenos prostaticos y sus usos | |
| CO2020013699A2 (es) | Composiciones aav, métodos de fabricación y métodos de uso | |
| AR117950A1 (es) | Receptores quiméricos de steap1 y composición farmacéutica que los contienen | |
| CL2016002142A1 (es) | Proteínas de fusión tatk-cdkl5, composiciones, formulaciones y uso de estas | |
| CO2021013970A2 (es) | Células t específicas del antígeno del virus multi-respiratorio y métodos para fabricar y usar el mismo terapéuticamente | |
| MX2020004063A (es) | Sistemas y metodos para producir celulas b modificadas geneticamente para expresar anticuerpos seleccionados. | |
| BR112021024855A2 (pt) | Composições de vírus adenoassociados para transferência de gene arsa e métodos de uso das mesmas | |
| MX374756B (es) | Organizacion de vector de expresion, metodos novedosos de generacion de celulas de produccion y su uso para la produccion recombinante de polipeptidos. | |
| AR069885A1 (es) | Metodos para producir el virus de estomatitis vesicular (vsv) atenuado en un cultivo celular y para mejorar el empaque del vsv de propagacion defectuosa, composicion inmunogenica, celula aislada y secuencia de control transcripcional | |
| BR112023018832A2 (pt) | Composições de proteínas de fusão quiméricas modificadas e métodos de uso das mesmas | |
| CL2021003328A1 (es) | Composiciones que comprenden iga secretora y probióticos. | |
| BR112023004874A2 (pt) | Construções de ácido nucléico, vetores virais e partículas virais |